Lineage Cell Therapeutics (XTAE:LCTX) Price-to-Tangible-Book : 13.20 (As of May. 20, 2024)

View and export this data going back to 2015. Start your Free Trial

What is Lineage Cell Therapeutics Price-to-Tangible-Book?

As of today (2024-05-20), Lineage Cell Therapeutics's share price is ₪3.921. Lineage Cell Therapeutics's Tangible Book per Share of Mar. 2024 for the quarter that ended in Mar. 2024 was ₪0.30. Hence, Lineage Cell Therapeutics's Price to Tangible Book Ratio of today is 13.20.

The historical rank and industry rank for Lineage Cell Therapeutics's Price-to-Tangible-Book or its related term are showing as below:

XTAE:LCTX' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.27 Med: 3.41 Max: 31.14
Current: 13.52

During the past 13 years, Lineage Cell Therapeutics's highest Price to Tangible Book Ratio was 31.14. The lowest was 1.27. And the median was 3.41.

XTAE:LCTX's Price-to-Tangible-Book is ranked worse than
91.79% of 1230 companies
in the Biotechnology industry
Industry Median: 2.81 vs XTAE:LCTX: 13.52

A closely related ratio is called PB Ratio. As of today, Lineage Cell Therapeutics's share price is ₪3.921. Lineage Cell Therapeutics's Book Value per Sharefor the quarter that ended in Mar. 2024 was ₪1.42. Hence, Lineage Cell Therapeutics's P/B Ratio of today is 2.77.

Lineage Cell Therapeutics Price-to-Tangible-Book Historical Data

The historical data trend for Lineage Cell Therapeutics's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lineage Cell Therapeutics Price-to-Tangible-Book Chart

Lineage Cell Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Price-to-Tangible-Book

Get a 7-Day Free Trial

2.12

6.02

10.24

11.30

30.08

Lineage Cell Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Price-to-Tangible-Book	Get a 7-Day Free Trial															18.50	15.54	20.34	30.08	17.37

Competitive Comparison of Lineage Cell Therapeutics's Price-to-Tangible-Book

For the Biotechnology subindustry, Lineage Cell Therapeutics's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Lineage Cell Therapeutics's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lineage Cell Therapeutics's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Lineage Cell Therapeutics's Price-to-Tangible-Book falls into.

Lineage Cell Therapeutics Price-to-Tangible-Book Calculation

Lineage Cell Therapeutics's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book	=	Share Price	/	Tangible Book per Share (Q: Mar. 2024 )
	=	3.921	/	0.297
	=	13.20

It can also be calculated from the numbers for the whole company:

Price to Tangible Book	=	Market Cap	/	Tangible Equity
	=	Market Cap	/	(Total Stockholders Equity	-	Preferred Stock	-	Intangible Assets)

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.

Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.

Lineage Cell Therapeutics Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of Lineage Cell Therapeutics's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.

Lineage Cell Therapeutics (XTAE:LCTX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lineage Cell Therapeutics Inc (XTAE:LCTX) » Definitions » Price-to-Tangible-Book

Comparable Companies

Traded in Other Exchanges

LCTX:USA BT3:Germany

Address

2173 Salk Avenue, Suite 200, Carlsbad, CA, USA, 92008

Website

https://www.lineagecell.com

Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cell transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.